Intracutaneous irritation testing is a core biocompatibility study used to evaluate whether extractable substances from medical device materials can provoke localized irritation when introduced into living dermal tissue. Performed in accordance with ISO 10993-10, ISO 10993-23, and the corresponding GB/T 16886 series, this in vivo test is a routine requirement for regulatory submissions to authorities worldwide. This technical guide explains the test principle, sample preparation, scoring methodology, acceptance criteria, and typical applications of the intracutaneous irritation test for medical devices.
Technical Overview
The intracutaneous irritation test, also known as the intradermal reactivity test, is a fundamental component of the biological evaluation program for medical devices. Its purpose is to determine whether leachable or extractable chemical substances released from device materials, components, or final products can produce acute localized irritation when they come into contact with living tissue. Because many devices contact tissues that are far more sensitive than intact skin, such as mucosal membranes, breached surfaces, blood, or implanted sites, intradermal exposure represents a conservative and sensitive model for hazard identification.
The test is internationally standardized. Historically governed by ISO 10993-10, irritation testing has been reassigned under ISO 10993-23:2021, which specifies the intracutaneous test method, scoring system, and acceptance criteria. Sample preparation is defined in ISO 10993-12, and the overall biological evaluation strategy is established in ISO 10993-1 within a risk management framework aligned with ISO 14971. In China, the corresponding national standards are the GB/T 16886 series, notably GB/T 16886.10 and GB/T 16886.12. The United States Pharmacopeia (USP) also describes a comparable intracutaneous test under its biological reactivity chapters for polymeric materials.
The basic principle of the test is straightforward: aqueous (polar) and vegetable-oil (non-polar) extracts of the device are injected intradermally into the clipped dorsal skin of healthy albino rabbits, alongside matched blank extraction vehicles that serve as negative controls. At defined observation intervals, trained evaluators grade the injection sites for erythema (redness) and edema (swelling) on standardized scales, and the responses of test sites are compared statistically and descriptively against control sites to derive a Primary Irritation Index. Manufacturers routinely commission accredited third-party laboratories to perform this study in support of FDA 510(k) and PMA submissions, CE marking under the EU Medical Device Regulation (MDR), NMPA registration in China, and PMDA review in Japan.
Testing Samples
The intracutaneous irritation test is normally performed on extracts of the medical device rather than on the device itself, because the test assesses the biological effects of substances that migrate out of the materials during use. Sample preparation therefore has a decisive influence on the relevance and reproducibility of the study.
Polar Extracts
A polar extraction vehicle, typically physiological saline (0.9% sodium chloride for injection), is used to extract water-soluble leachables such as ionic residues, acidic or basic contaminants, polar processing additives, and sterilant residues. The polar extract is injected intradermally at multiple sites on one side of the rabbit's back, with the corresponding blank saline vehicle injected at paired control sites.
Non-Polar Extracts
A non-polar vehicle, most commonly sesame oil or cottonseed oil compliant with pharmacopeial specifications, extracts lipophilic substances such as plasticizers, oligomers, lubricants, colorants, and hydrophobic degradation products. The non-polar extract and its blank vehicle are injected at a separate set of sites, completing the dual-solvent extraction strategy recommended by the standards to cover the widest possible range of extractable chemistries.
Supplementary Extraction Vehicles
Depending on the device materials and the intended clinical use, additional vehicles such as ethanol/water mixtures or polyethylene glycol 400 (PEG 400) may be justified in the biological evaluation plan. The choice of vehicles must be scientifically rationalized and documented, particularly when devices are used with specific clinical fluids or when material characterization data indicate the presence of extractables with intermediate polarity.
Sample Preparation Requirements
Sample preparation follows ISO 10993-12 and must reflect the final product condition, including production, cleaning, and sterilization processes. Key parameters include:
- Surface-area-to-volume or mass-to-volume ratios, for example 6 cm²/mL for thin-walled films and tubing, 3 cm²/mL for thicker polymer or metallic sections, and approximately 0.2 g/mL for irregular or porous solids.
- Extraction conditions chosen to exaggerate, but not degrade, clinical leaching: 37°C for 24 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour, with the condition selected based on material tolerance.
- Sterile or aseptic handling after terminal sterilization, with extracts used promptly to prevent degradation, evaporation, or contamination.
- Documentation of device configuration, whether tested intact, cut into sections, or represented by representative material coupons.
Testing Items
The study delivers a structured set of observations and calculated endpoints that together determine whether the test sample meets the requirements of the standard:
- Erythema and eschar formation: graded from 0 to 4, ranging from no visible reaction through very slight, well-defined, and moderate erythema up to severe erythema with beef redness and eschar formation.
- Edema: graded from 0 to 4, ranging from no swelling through very slight, well-defined, and moderate edema up to severe edema extending beyond the raised area of injection.
- Primary Irritation Index (PII): the arithmetic mean of all erythema and edema scores recorded at the scheduled observation times, calculated separately for each extract and its blank control.
- Control-corrected irritation score: the difference between the mean score of the test extract sites and the mean score of the corresponding blank vehicle sites, which forms the basis of the pass or fail decision.
- Systemic observations: general condition, body weight, behavior, and mortality of the animals, recorded to rule out systemic toxicity confounders.
- Test validity checks: confirmation that blank control sites show minimal reactivity and that any gross lesions, adverse systemic findings, or control reactivity exceeding the limits defined in the standard trigger test rejection and repeat.
Testing Methods
Test Animal Selection
The standard test system is the healthy young adult albino rabbit, most commonly the New Zealand White strain, with a typical body weight of approximately 2 to 3 kg. A minimum of three animals is required, and animals must be acclimatized to the laboratory environment before the study, housed under controlled temperature, humidity, and light cycles, and maintained on certified feed and water. Animals with pre-existing skin lesions, prior dermal test exposure, or observable illness are excluded. The study is conducted under institutional animal welfare oversight and in compliance with applicable national animal care legislation and the principles of the 3Rs (replacement, reduction, refinement).
Injection and Dosing Procedure
Immediately before dosing, the dorsal area of each rabbit is clipped free of fur without abrading the skin. Using sterile technique, 0.2 mL of each preparation is injected intradermally using a fine-gauge needle, forming a visible bleb within the dermal layer. A typical design for each animal includes five sites dosed with the polar test extract and five sites with the polar blank, plus five sites with the non-polar test extract and five with the non-polar blank, arranged symmetrically so that test and control responses can be compared side by side on the same animal. Any air bubbles, extravasation, or failed injections are documented, and damaged sites are excluded from scoring.
Observation Schedule and Grading
Injection sites are examined and scored at approximately 24 hours, 48 hours, and 72 hours after injection, with an additional immediate post-dose check to confirm dosing integrity and detect early reactions. Scoring is performed by trained personnel using the standardized 0 to 4 scales for erythema and edema defined in ISO 10993-23 and GB/T 16886.10, ideally under blinded conditions to minimize observer bias. Descriptions of the size, extent, and character of each reaction, including eschar formation or blanching, are recorded in the raw data, and representative photographic documentation is commonly included in the final report.
Data Analysis and Acceptance Criteria
For each extract and its blank, the total irritation score is the sum of all erythema and edema scores at all observation points divided by the total number of readings, yielding the Primary Irritation Index. The key decision criterion is the difference between the mean score of the test extract and the mean score of the blank control: a difference of 1.0 or less indicates that the test sample meets the requirements of the intracutaneous test, whereas a difference greater than 1.0 identifies the sample as a potential dermal irritant requiring follow-up chemical characterization and risk assessment. The test is considered invalid and must be repeated if blank control responses exceed the limits specified in the standard, if more than the permitted proportion of animals shows confounding reactions, or if systemic toxicity occurs. The overall study timeline, including acclimatization, extraction, dosing, observation, and report issuance, is typically three to five weeks at an experienced accredited third-party laboratory.
Applications
Intracutaneous irritation testing is selected according to the nature and duration of body contact defined in the ISO 10993-1 and GB/T 16886.1 evaluation matrices. Typical applications include:
- Surface medical devices contacting breached or compromised skin and mucosal membranes, such as advanced wound dressings, hydrogels, catheter fixation devices, and topical delivery systems.
- External communicating devices, including intravenous and arterial catheters, infusion sets, extracorporeal circulation tubing, blood dialyzers, endotracheal tubes, breathing circuit components, and laparoscopic instrument insulation exposed to tissue.
- Implantable devices and surgical materials, such as orthopedic implants, absorbable scaffolds, hemostatic agents, pacemaker leads, and tissue adhesives, where direct tissue contact makes irritation screening mandatory.
- Materials and component qualification programs, where suppliers of polymers, elastomers, coatings, adhesives, and biodegradable resins use intracutaneous data to support material master files and customer audits.
- Change control and post-market activities, including evaluation of new suppliers, altered sterilization methods such as ethylene oxide or gamma irradiation parameter changes, reformulated plastics, revised cleaning processes, and reprocessing of reusable devices.
- Regulatory submissions across major jurisdictions, supporting FDA device submissions in the United States, technical documentation under the EU MDR, NMPA registration dossiers in China, and MHLW/PMDA submissions in Japan, where the data are reviewed as part of the overall biological safety file.
FAQ
What is the difference between the intracutaneous test and the skin irritation test?
The skin irritation test, described in ISO 10993-23 and GB/T 16886.23, applies device extracts or materials to intact or abraded epidermis under occlusive patches and evaluates surface reactions. The intracutaneous test bypasses the protective barrier of the epidermis by injecting extracts directly into the dermis, making it substantially more sensitive and better suited to devices contacting internal tissues, breached surfaces, or blood. The two tests serve complementary roles within the irritation section of the biological evaluation plan.
When is intracutaneous irritation testing required?
The requirement is driven by the ISO 10993-1 categorization matrix. Devices with limited, prolonged, or permanent contact with breached skin, mucosal membranes, blood, tissue, or implant sites generally require irritation data, and the intracutaneous route is the standard approach for extract-based evaluation. Devices contacting only intact skin for short durations may often satisfy irritation endpoints with skin irritation testing or documented equivalence to clinically established materials.
Which standards govern the test?
The method, scoring, and acceptance criteria are specified in ISO 10993-23:2021, which superseded the irritation content of ISO 10993-10:2010, together with ISO 10993-12 for sample preparation and ISO 10993-1 for evaluation planning. In China, the harmonized national equivalents GB/T 16886.10 and GB/T 16886.12 are cited in NMPA submissions, while the USP biological reactivity chapters provide an alternative framework frequently referenced for polymeric materials in the United States.
Why are both polar and non-polar extracts tested?
Medical device materials can release both water-soluble and lipid-soluble substances. Physiological saline extracts polar leachables, while sesame or cottonseed oil extracts non-polar additives such as plasticizers and oligomers. Testing both vehicle types ensures that the biological evaluation covers the full spectrum of potentially irritating extractables, in line with the requirements of ISO 10993-12.
How are the results interpreted?
The Primary Irritation Index is calculated for each extract and compared with its blank control. If the difference between the test extract mean score and the blank mean score is 1.0 or less, the sample meets the requirements of the test. Larger differences indicate irritant potential and should trigger chemical characterization, extractables and leachables analysis, material reformulation, or a documented toxicological risk assessment to justify clinical acceptability.
Can the intracutaneous test be replaced by in vitro methods?
Currently, validated in vitro reconstructed human epidermis models address the skin irritation endpoint for certain extract types under ISO 10993-23, but no validated in vitro alternative has been accepted by major regulators as a full replacement for the intracutaneous irritation test in dermal tissue. Manufacturers should discuss any proposed in vitro strategy with the relevant competent authority or conform to the expectations of accredited third-party laboratories experienced in biocompatibility programs before finalizing the test plan.